Evidence map›Paper›PMID 29234495›Full record

ArticleJournal of intensive care2017

Response of letter to the editor on Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy.

R Saikant, Shilpa Ravindran, Ashitha Vijayan, Vani Maya, S Lakshmi, R Kartik, Manoj G

Open access · goldAbstract readLetter
In one paragraph

Article in Journal of intensive care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Point-of-critical-care diagnostics for sepsis enabled by multiplexed micro and nanosensing technologies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

R SaikantDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
Shilpa RavindranDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
Ashitha VijayanDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
Vani MayaDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
S LakshmiDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
R KartikDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
Manoj GDiagnostic Products Division and Cell Culture facility, Corporate R&D Centre, HLL Lifecare Limited, Sreekariyam (P.O), Kerala, Trivandrum, India.
HLL Lifecare (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a letter to the editor, Raineri SM et al. have given an insight of another dimension of procalcitonin (PCT) use as a diagnostic tool in invasive candidiasis. But based on our preliminary information, PCT is reported as unconventional modes of diagnosis approach which yet to prove its stand-alone biomarker properties for invasive candidiasis.

Identifiers

PMID29234495
PMCPMC5719722
OpenAlexW2771977515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.